Medical Cannabis for Cancer in Israel: Access, Evidence and Cost

Oncology is where Israel's medical cannabis programme began. The Ministry of Health started issuing approvals for cancer symptom relief back in 2007, years before pain and PTSD became the programme's largest indications, and cancer patients remain one of the most firmly established categories today (Bar-Lev Schleider et al., European Journal of Internal Medicine, 2018). This guide explains who qualifies, how a cancer patient actually obtains a licence, what the Israeli evidence shows, and what it costs.

This guide is informational and is not medical advice. Cancer treatment decisions — including whether to use cannabis alongside chemotherapy, immunotherapy or radiotherapy — should be made with your treating oncologist.

An important distinction: symptoms, not a cure

Israel's programme authorises cannabis for cancer as a supportive (palliative) therapy — to manage symptoms and the side effects of treatment, not as an anti-tumour cure. The Ministry of Health frames eligibility around patients with active oncological disease or those undergoing chemotherapy, immunotherapy or radiotherapy, for control of symptoms such as nausea, vomiting, appetite loss, weight loss, pain and sleep disturbance (Ministry of Health). Laboratory work on cannabinoids and tumour cells continues, much of it rooted in the Israeli research tradition, but that is a research question — it is not the basis on which licences are granted. Confusing the two is the single most common misunderstanding patients bring to their oncologist.

Do cancer patients qualify?

Yes — cancer is among the clearest qualifying indications in the Israeli system, sitting in the "oncology" group alongside chronic pain, PTSD and a defined list of neurological and gastrointestinal conditions (see our full guide to qualifying conditions for medical cannabis in Israel). Since the reform that took effect in January 2024, the old "last resort" rule — requiring that every conventional treatment be exhausted first — has been dropped in favour of the treating specialist's clinical discretion (Journal of Cannabis Research, 2025). For a cancer patient, that specialist is normally the oncologist managing the case, who is best placed to weigh cannabis against the specific disease, treatment stage and other medications.

How a cancer patient gets a licence

The pathway follows the same structure as the rest of the programme, but the entry point is the oncology clinic rather than a family doctor:

1. The oncologist recommends. A family physician generally cannot initiate a cannabis request; the recommendation must come from a relevant specialist — for cancer, the treating oncologist (Ministry of Health).
2. The recommendation is documented. It records the diagnosis, current treatment, symptoms being targeted, and the proposed cannabis therapy — including the route (oil, flower, capsule) and the THC/CBD profile.
3. Approval and authorisation. The recommendation is processed by the Medical Cannabis Unit (Yakar) or, for many indications, handled within the patient's HMO; if approved, the patient receives an authorisation specifying monthly dosage and duration.
4. Dispensing. Product is collected from a pharmacy licensed to dispense cannabis, within the authorised dosage.

For the step-by-step version that applies across all conditions, see how to get a medical cannabis licence in Israel.

What the Israeli evidence actually shows

Israel has produced some of the largest real-world datasets on cannabis in oncology, which is why this indication is taken seriously here. The landmark study is Bar-Lev Schleider and colleagues' 2018 prospective analysis of 2,970 cancer patients treated through the Israeli programme between 2015 and 2017 (European Journal of Internal Medicine, 2018). Among the patients who completed six months of follow-up, 95.9% reported improvement in their condition, with quality-of-life scores rising from about 20% at baseline to roughly 70% after six months; the treated group averaged 59.5 years and was 54.6% women (PubMed summary).

Those numbers are striking, but they deserve an honest caveat. This was an observational cohort, not a randomised controlled trial, so it captures how patients fared on cannabis rather than proving cannabis caused every improvement — expectation effects and the natural course of care both play a role. Later Israeli work has also highlighted practical limits: a prospective cohort found meaningful non-adherence among oncology patients, meaning a share of those prescribed cannabis do not stay on it, often due to side effects or cost (Complementary Therapies in Medicine, 2026). The reasonable reading: for symptom relief in cancer, the real-world signal is genuinely encouraging, while the gold-standard trial evidence remains thinner.

What it costs

Medical cannabis is not included in Israel's national health basket, so cancer patients — like other indications — largely pay out of pocket. Expect deductible-style HMO charges for the medical examination, the permit and the prescription, then the product cost at the pharmacy, where legal flower commonly runs in the range of roughly ₪100–350 per 10 grams depending on product and outlet. Monthly cost tracks the prescribed dosage. For the full fee breakdown and who qualifies for funded treatment, see how much medical cannabis costs in Israel.

Practical guidance

Start the conversation with the oncologist already treating you — they can move fastest and are the required prescriber. Be specific about which symptoms you want to address (nausea during chemo, appetite, sleep, pain), since that shapes the product profile. Discuss interactions frankly: cannabis can interact with some oncology drugs and sedatives, which is exactly why oncologist-led prescribing matters. And build in time — approvals and renewals are not instant.

For the bigger picture of patient access, return to our Patients hub; for related indications, see medical cannabis for chronic pain in Israel and medical cannabis for PTSD in Israel.